INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 133 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2015. The put-call ratio across all filers is 2.26 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,624,516 | -16.5% | 146,372 | +1.5% | 0.00% | 0.0% |
| Q2 2023 | $9,126,882 | +95.7% | 144,139 | +67.4% | 0.00% | +50.0% |
| Q1 2023 | $4,663,777 | +9.3% | 86,127 | +6.8% | 0.00% | 0.0% |
| Q4 2022 | $4,265,828 | +13.2% | 80,609 | -0.5% | 0.00% | +100.0% |
| Q3 2022 | $3,770,000 | -21.1% | 81,029 | -3.2% | 0.00% | -50.0% |
| Q2 2022 | $4,779,000 | +0.6% | 83,731 | +7.9% | 0.00% | +100.0% |
| Q1 2022 | $4,750,000 | +37.0% | 77,627 | +17.2% | 0.00% | 0.0% |
| Q4 2021 | $3,466,000 | +54.2% | 66,224 | +9.8% | 0.00% | 0.0% |
| Q3 2021 | $2,248,000 | +17.7% | 60,295 | +28.8% | 0.00% | 0.0% |
| Q2 2021 | $1,910,000 | +20.3% | 46,803 | +0.1% | 0.00% | 0.0% |
| Q1 2021 | $1,588,000 | +23.7% | 46,774 | +15.9% | 0.00% | 0.0% |
| Q4 2020 | $1,284,000 | +23.3% | 40,369 | -0.5% | 0.00% | – |
| Q3 2020 | $1,041,000 | -3.2% | 40,555 | -3.2% | 0.00% | -100.0% |
| Q2 2020 | $1,075,000 | +166.1% | 41,877 | +59.3% | 0.00% | – |
| Q1 2020 | $404,000 | -44.3% | 26,285 | +24.5% | 0.00% | – |
| Q4 2019 | $725,000 | +433.1% | 21,107 | +15.9% | 0.00% | – |
| Q3 2019 | $136,000 | -34.9% | 18,215 | +13.5% | 0.00% | – |
| Q2 2019 | $209,000 | +6.6% | 16,044 | 0.0% | 0.00% | – |
| Q1 2019 | $196,000 | +7.1% | 16,044 | 0.0% | 0.00% | – |
| Q4 2018 | $183,000 | -42.6% | 16,044 | +9.4% | 0.00% | – |
| Q3 2018 | $319,000 | +23.2% | 14,670 | 0.0% | 0.00% | – |
| Q2 2018 | $259,000 | -20.8% | 14,670 | -5.5% | 0.00% | – |
| Q1 2018 | $327,000 | +20.7% | 15,532 | -16.4% | 0.00% | – |
| Q4 2017 | $271,000 | +1.9% | 18,590 | +9.7% | 0.00% | – |
| Q3 2017 | $266,000 | +160.8% | 16,942 | +105.7% | 0.00% | – |
| Q2 2017 | $102,000 | -23.9% | 8,235 | 0.0% | 0.00% | – |
| Q1 2017 | $134,000 | +5.5% | 8,235 | -1.4% | 0.00% | – |
| Q4 2016 | $127,000 | +98.4% | 8,350 | +89.9% | 0.00% | – |
| Q3 2016 | $64,000 | -67.7% | 4,398 | -16.7% | 0.00% | – |
| Q2 2016 | $198,000 | +76.8% | 5,282 | +29.3% | 0.00% | – |
| Q1 2016 | $112,000 | -38.1% | 4,085 | +22.2% | 0.00% | – |
| Q4 2015 | $181,000 | +42.5% | 3,343 | 0.0% | 0.00% | – |
| Q3 2015 | $127,000 | +23.3% | 3,343 | 0.0% | 0.00% | – |
| Q2 2015 | $103,000 | +25.6% | 3,343 | 0.0% | 0.00% | – |
| Q1 2015 | $82,000 | +36.7% | 3,343 | 0.0% | 0.00% | – |
| Q4 2014 | $60,000 | +25.0% | 3,343 | 0.0% | 0.00% | – |
| Q3 2014 | $48,000 | – | 3,343 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |